Urbino

Researchers are evaluating the clinical and health-related outcomes of amivantamab-containing treatment regimens for patients with common EGFR-mutated advanced non-small cell lung cancer NSCLC, including metastatic cases where the cancer has spread. This study observes these treatments in a real-world setting, focusing on patients with specific EGFR mutations exon 19 deletions or exon 21 L858R substitution. It aims to describe how these regimens perform outside of controlled clinical trials. Participants are grouped into two cohorts one receiving amivantamab combined with carboplatin and pemetrexed after prior therapy failure, and another receiving amivantamab with lazertinib as first-line therapy. Treatments are given according to usual clinical practice, and no study drugs are provided. Data collection captures information from routine care, including treatment administration and related medications. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, concomitant medication use, and quality of life measures using validated questionnaires. Monitoring continues for up to approximately 60 months. Participants provide informed consent, and all data comes from standard medical records without additional interventions or procedures required by the study.

This research aims to gather a large group of patients suspected of having coronary artery disease CAD who underwent Computed Tomography Coronary Angiography CTCA to better understand how CTCA helps in identifying the presence and severity of CAD and predicting patient outcomes. The study focuses on assessing the added value of CTCA to current methods in determining disease burden and cardiovascular risk. It is an observational retrospective study analyzing data collected from patients evaluated with CTCA over the past several years. Patients included in the study had CTCA performed using at least 64-slice CT technology or 16-slice with more than 4 years follow-up and had a calcium score available. The study collects data retrospectively from institutional databases, including clinical history, CTCA results, and follow-up records. Patients were classified based on CTCA findings into groups with normal arteries, non-obstructive CAD, or obstructive CAD. Data include detailed CT scanning protocols and administration of medications like beta-blockers and nitroglycerine during imaging. Participants information, such as cardiovascular risk factors and symptoms, was collected from clinical databases and interviews. Outcomes tracked include major adverse cardiovascular events MACE, coronary revascularizations, and shifts in cardiovascular risk categories. Follow-up data were obtained through outpatient visits, phone contacts, and medical records review, with a minimum follow-up of 6 to 12 months. Researchers analyze outcomes using various statistical methods to identify predictors of risk and the incremental value of CTCA in prognosis.

Researchers are evaluating a mobile health m-health solution designed to support self-management skills in adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. This randomized clinical trial compares the use of the personalized m-health tool integrated with the Electronic Patient Record EPR against usual diabetes care, focusing on changes in glycated hemoglobin HbA1c levels over an 18-month period. The study aims to enhance patients abilities to manage their condition through technology combined with healthcare collaboration. Participants are randomly assigned to one of two groups the treated group receives regular care plus access to the m-health solution, while the control group continues with standard care alone. The m-health solution includes mobile apps for tracking health data such as blood sugar, lifestyle habits, and diet, receiving alerts and motivational messages, communicating with healthcare professionals, and accessing educational materials. Healthcare providers will monitor patient data through an integrated platform and communicate as needed. The intervention begins at diabetic centers and continues at participants homes. Participants will undergo evaluations at the start and at 6, 12, and 18 months, including clinical assessments, questionnaires, and data collected from the m-health solution. Researchers will assess changes in diabetes severity, medication adherence, lifestyle habits, self-efficacy, quality of life, and the usability and satisfaction with the m-health tool. There are no additional visits or lab tests beyond usual care. The study includes cost-effectiveness analysis and gathers participant feedback to understand their experience with the intervention.